OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear

824 Projects | 572 Researchers | $406,233,331 Invested

2026

Switch Therapeutics

Anindya Bhattacharya, PhD

Developing a novel, conditionally activated siRNA (CASi) molecule for treatment of Alzheimer’s Disease

  • Funding Amount: $2,736,900
  • Organization Type:
  • Program: Drug Discovery
  • Target: ApoE, Lipids and Lipoprotein Receptors
  • Status: Active

2026

Albert Einstein College of Medicine

Thomas Leyh, Phd

Small Molecule Prevention of Alzheimer’s Disease

  • Funding Amount: $518,313
  • Organization Type:
  • Program: Drug Discovery
  • Target: ApoE, Lipids and Lipoprotein Receptors
  • Status: Active

2026

Columbia University Irving Medical Center

Chaolin Zhang, PhD

Novel ASO therapeutics to rebalance 3R/4R tau isoforms for frontotemporal dementia and other tauopathies

  • Funding Amount: $349,907
  • Organization Type:
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2026

Washington University in St. Louis

Timothy Miller, MD, PhD

Optimizing a Gene-Targeted Therapeutic to Enhance TBK1 Expression in Genetic FTD

  • Funding Amount: $348,007
  • Organization Type:
  • Program: Drug Discovery
  • Target: Other
  • Status: Active

2026

MindImmune Therapeutics, Inc.

Leonid Gorelik

MITI-101, a novel antibody therapeutic to treat Alzheimer's disease and related disorders

  • Funding Amount: $5,014,485
  • Organization Type:
  • Program: Clinical
  • Target: Inflammation
  • Status: Active

2026

Washington University in St. Louis

Randall Bateman, MD

Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN)

  • Funding Amount: $1,000,000
  • Organization Type:
  • Program: Drug Discovery
  • Target: Multi-Target
  • Status: Active

2025

Superfluid Dx

Bojk Berghuis

Integrating cfRNA and Proteomics with AI for Next-Generation Alzheimer’s Diagnostics

  • Funding Amount: $911,250
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

Alzheimer's Disease Data Initiative (ADDI)

Farhad Imam

The Global Neurodegeneration Proteomics Consortium: V2 expansion for ADNI and other key AD datasets

  • Funding Amount: $1,881,800
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

University of California - San Francisco

Kristine Yaffe, MD

Long-term follow-up of the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)

  • Funding Amount: $243,515
  • Organization Type:
  • Program: Prevention
  • Target: Other
  • Status: Active

2025

Biogen

Alexis Moscoso, PhD

Longitudinal Study with Positron Emission Tomography Using [¹⁸F]PI-2620 in Primary Tauopathies

  • Funding Amount: $599,992
  • Organization Type:
  • Program: Biomarkers
  • Target: Tau
  • Status: Active
View More